Clinical Trials on Moderate Chronic Plaque Psoriasis in Hungary

Total 52 results

UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
Sun Pharmaceutical Industries Limited

Recruiting

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Hungary, India, Poland, Spain, Slovakia
Fresenius Kabi SwissBioSim GmbH
Merck KGaA, Darmstadt, Germany

Completed

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO)

Psoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type Psoriasis

United States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
AbbVie (prior sponsor, Abbott)

Completed

Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Moderate to Severe Plaque Psoriasis

Czech Republic, Estonia, Hungary, Israel, Romania, Slovakia, Slovenia, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Szeged University

Recruiting

Evaluation of the Effect of Sulphur Mineral, Thermal Water on Skin Microbiome in Plaque Psoriasis, a Pilot Study

Plaque Psoriasis

Hungary
Pfizer

Completed

Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis

Plaque Psoriasis

Hungary
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 2)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
UCB Biopharma S.P.R.L.
Parexel

Completed

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 1)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
Maruho Europe Limited
Maruho Co., Ltd.

Completed

Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients

Plaque Psoriasis

Germany, Austria, Bulgaria, Hungary, Lithuania, Poland
Sandoz
Hexal AG

Completed

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (EGALITY)

Chronic Stable Plaque Psoriasis

Germany, Romania, Bulgaria, Czech Republic, Estonia, Hungary, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
AbbVie

Active, not recruiting

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

Chronic Plaque Psoriasis

Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
Novartis Pharmaceuticals

Completed

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Chronic Severe Plaque-type Psoriasis

Belgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE)

Chronic Plaque Psoriasis

Germany, United States, Colombia, Italy, Spain, Belgium, Egypt, Hungary, Australia, Singapore, France, Sweden, Guatemala, Philippines, Korea, Republic of, United Kingdom, Argentina, Poland, Romania, Canada, Iceland, India, Finland
Actelion

Completed

ACT-128800 in Psoriasis

Plaque Psoriasis

Germany, Hungary, Austria, France, Serbia
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Evelo Biosciences, Inc.

Completed

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United Kingdom, Hungary, Poland, United States
Galderma R&D

Completed

Plaque Psoriasis Study in Pediatric Subjects

Plaque Psoriasis

United States, Spain, Germany, Italy, Belgium, Canada, Hungary
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Plaque Psoriasis

Germany, Spain, Belgium, France, Hungary, Austria, Canada, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis (STEPin)

Plaque Psoriasis

Spain, United Kingdom, Estonia, Germany, Bulgaria, Finland, Hungary, Poland, Argentina, Canada, Denmark, Switzerland, Sweden
Pfizer

Completed

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis (PRISTINE)

Psoriasis | Plaque Psoriasis

Spain, Taiwan, Germany, Korea, Republic of, Belgium, Greece, Hungary, Argentina, Austria, Czech Republic, Italy, Mexico, Thailand
UCB Biopharma S.P.R.L.

Completed

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1)

Psoriasis | Plaque Psoriasis

United States, Canada, Czechia, Germany, Hungary
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Bulgaria, Russian Federation, Estonia, Hungary, Latvia, Poland, Ukraine, Germany
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL)

Plaque Psoriasis

United States, Korea, Republic of, Hungary, United Kingdom, Canada, Germany, Poland, Turkey, Taiwan, Spain, Argentina
DICE Therapeutics, Inc., a wholly owned subsidiary...

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis (Illuminate)

Plaque Psoriasis

Canada, Hungary, Germany, Spain, United States, Poland, United Kingdom, Czechia
Takeda

Recruiting

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Plaque Psoriasis

United States, Canada, Bulgaria, Hungary
Amgen

Completed

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Poland, Estonia, Germany, Hungary, Latvia, Lithuania
Eli Lilly and Company

Completed

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds)

Plaque Psoriasis

United States, Spain, Puerto Rico, Czechia, Canada, Germany, France, Poland, Hungary, Mexico, Russian Federation, Argentina, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Plaque Psoriasis

United States, Korea, Republic of, Taiwan, Germany, Poland, Brazil, Spain, Hungary, Australia, Canada, Romania
Eli Lilly and Company

Completed

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

Plaque Psoriasis

Argentina, Puerto Rico, United States, Australia, Taiwan, Japan, Hungary, Korea, Republic of, Mexico, Germany, Poland, Romania, Czechia, Canada
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Novartis Pharmaceuticals

Completed

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis (CLARITY)

Plaque Psoriasis

United States, Hungary, Malaysia, Czechia, Korea, Republic of, Guatemala, Poland, Vietnam, Canada, Iceland, Slovakia
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Plaque Psoriasis

China, Thailand, Philippines, Turkey, Hungary, Malaysia
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

Plaque Psoriasis

Germany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Australia, Spain, Argentina, Japan
UCB Biopharma S.P.R.L.

Completed

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (CIMPACT)

Psoriasis | Plaque Psoriasis

United States, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Korea, Republic of, United Kingdom, United States, Poland, Germany, Brazil, Spain, Taiwan, Hungary, Japan, Canada, Argentina, Australia
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Protagonist Therapeutics, Inc.

Completed

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe

United States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
Janssen Research & Development, LLC

Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)

Crohn Disease | Arthritis, Psoriatic | Colitis, Ulcerative

Belgium, France, United States, Hungary, Japan, United Kingdom, Germany, Poland, Argentina
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
Ferring Pharmaceuticals

Completed

Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study) (OPTIMISE)

Mild-to-moderate Ulcerative Colitis

Poland, Hungary, Italy, Czechia, Netherlands, Slovakia
Galderma R&D

Completed

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus (NemoCKDaP)

Chronic Kidney Disease Associated Moderate to Severe Pruritus

Spain, United States, Hungary, Poland

Clinical Trials on Moderate Chronic Plaque Psoriasis in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations